Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Protein ligand, virus ligand, it's all the same. You can't design a cell membrane that a virus will preferentially attack. It's nonsense... or is it!?
Either way, you probably can't get the ADME good enough for the idea to work. Hence the delay in human studies.
And then the final blow is the impossibility of halting the virus when one needs to - when it is in the cell. The folks who don't get HIV despite exposure have a cell surface CCR mutation that stops the virus from entering immune system cells. Destroying viruses in the bloodstream is meaningless.
Lol! Short this stock and continue to compound with the profits? What I've been doing for years.
I wonder what the PK is for a 'cide. Forget 'billions' - that's amateur talk. Let's talk real PK - dose per ug, ng. Peak/trough concentrations.
You came up with the one actual piece of diligence that is worth anything in the few days I've been here. For that I'm thankful and grateful. The claims in that patent are very illustrative. They show exactly what the drug is and how it works. It's just a polymer with a virus ligand attached. The polymer serves a stability function?
The problem here is there is no such thing as a "virus ligand". The idea that viruses (thanks for whoever pointed out virii is strictly a computing jargon term) will be attracted to this "fake cell" is humorous. There are so many alternatives (trillions) for host cells in the body that installing enough fake cells is not going to be met well. More to follow, but great job!
How could any short seller be desperate with NNVC? I've shorted about 400,000 shares in the last few months and the stock is near all-time lows. The company is a farce.
By your logic, all bad looking ideas are good ones, then?
The borrow will free up with time. I'm approaching 500,000 short position soon. No big deal. Stock went from 2 to 1. No problem going from 1 to 0.50. The insider sellers don't care.
But nary a borrow!
Did we really land on the moon? This and other truths at 9.
Never has happened in the history of investing.
Tried to short more. Couldn't find the locate on a fresh 100,000.
You didn't mention StatSure.
This is useful and I will comment shortly. Thank you.
Too bad Seymour is quite old and has failed at everything he has tried to accomplish. Check out his prior attempt at being a CEO.
Trillions of cells in the human body. This is a bad idea.
Total number of holders: 3
Actually it's down to 2, and the largest one has 88,900 shares.
How are we in deep? The stock is down 50% from recent highs.
If there was a publication the stock would go up 30% in my opinion.
That's only a half a million dollars. This isn't a joke or a game to me. Like I said, there is no one else to discuss the stock with... no sell-side analysts, no institutional investors, just you folks.
Who are they? I'm curious to learn more. Typically institutional investors file 13F filings, containing their holdings. Services like Bloomberg aggregate these holdings.
Here is what it says on Bloomberg for NNVC (Bloomberg is an expensive service you do not have):
Theracour Pharma | 33,006,018 | 24.96% | -561,937 | 6/24/10
Diwan Anil | 11,000,000 | 8.32% | 0 | 2/17/09
Seymour Eugene | 8,500,000 | 6.43% | 0 | 2/17/09
Pacific West Fina| 88,900 | 0.07% | -13,500 | 6/30/10
Wesbanco Bank Whe| 20,000 | 0.02% | 0 | 6/30/10
Haberer Registere| 0 | 0.00% | -10,000 | 6/30/10
Pretty pathetic. Virtually every other healthcare company has pages and pages of institutional investor holding data. Go on a Bloomberg and check (sometimes they're available at fancy restaurants in NYC or universities).
It's been working pretty well, lately, that's for sure, LOL!
Not really. Warren Buffett started with $100 with the same philosophy and is not done and has $50 billion+. It's about compounding friend, not about throwing some hail mary pass and hoping for the best.
You're calculating wrong. I have a 50% potential return in 12 months. That's a big deal. I've already made a substantial return in a short time. Compounding returns is how I grow my wealth.
If it's really associated with fine minds and institutions, why is there not one institutional investor? Or even a research analyst? Or a real investment bank (Midtown Partners, LOL)?
A real office space? A real infrastructure... A real anything?
I will let you know. I'm up to 363,000 short. I think I will probably stop at around 1 million. This should not effect the stock price in any way as the volume is more than this. If the fundamentals of the company are good, the stock will rise. If they're not, the stock will fall.
It's possible, and there are other companies that refuse to disclose structures for this reason (NYMX). Usually you can disclose at least ONE structure.
Anyway, there are still 3 more concerns that they have no answer to. No institutional shareholder? NYMX has those. Every other company can meet all 4 requires or 3 in the very rare cases. This company can't claim one of my 4 requirements. It really stands out on the fraud-o-meter.
Why no real investors???
I'm up to several hundred thousand short. Looks like free money in a short period of time. Like I said, GENZ annualized at 14% per year. NNVC is down 50% from its peak. 50% annualizing is much better than 14%. It's tempting to think you can get a million shares of GENZ, but the reality is the math is wrong.
This does seem like a group that could use the reminder. I asked for a chemical structure and was shown an electron micrograph. Not quite the resolution the world is used to.
Chemical structure of a drug doesn't matter? How long have you been investing, LOL? Having a rough idea of the composition of a drug determines its likelihood of success. Antibodies are too large to cross the blood-brain-barrier, for instance. They're also antigenic. Small molecules administered orally require excellent metabolic profile and lipophilicity. Etc, etc. Not knowing what the drug looks like on paper is very sketchy.
I think the silence is deafening with respect to some of my very simple questions. Why can every single other healthcare company developing a drug answer my 4 basic questions, but NNVC can't answer a single one?
I'm shorting 25,000 at the moment with a 0.99 limit. We'll see what happens.
There's nothing that's more common knowledge in medicine than how safe HIV drugs have become in the last two decades, especially the last 10 years.
http://www.ncbi.nlm.nih.gov/pubmed/19959410
Abstract
The introduction of integrase inhibitors as a new drug class for treatment of HIV have added a very potent and extremely well tolerated new treatment option to the HIV-armentarium. Particularly in patients with previously developed drug resistance, the availability of new active drugs offers great hope. Moreover, the in general excellent safety profile offers numerous opportunities for all lines of therapy and special patient populations. Clearly more data is needed to further explore and define the future role of integrase inhibitors in HIV-care.
It would be great if the company had a full-time CEO, an IR person or a CFO. Those things would be great.
Or if they could meet any of the 4 requirements I laid out that every other biotech/pharmaceutical company (I monitor hundreds of them) can meet.
If anyone can prove the company has done any of the below, or if they ever do, I will do basically anything in return.
Keep in mind these are very simple things to do from a drug company's perspective. I CANT THINK OF ONE company that hasn't done at least one of these things, if not all 4. How much worse does it get??? I'll buy 5,000 shares for every person here. I'll buy 1,000,000 shares for myself. It's just not a real drug company, sadly.
1. Filing an IND as promised for many years.
2. Obtaining just ONE institutional investor who believes in the company. Sorry, you don't count.
3. Displaying the chemical structure of one of their compounds.
4. Having more than a few million dollars of cash on the balance sheet.
Um, there are three or four people that work at Nanoviricides. I know who works there. I can call them anytime. I have.
You're just wildly wrong on this one like everything else. HAART is about as safe as it gets. Not many people die taking Atripla or Combivir :) They have almost no side effects. Google doesn't solve your problem, sorry.
HAART does not have deadly side effects, LOL.
All good to me. Good luck with your investment. Nothing wrong with trusting someone. I think you're wrong but I agree with your method--it will serve you well and I bet it already has.
Medicines have side effects. Thanks for showing me the way. I didn't mention any of those.
Oh, and more importantly, 99% of healthcare companies can answer either 3 or 4 of those criteria. NNVC is the only company I'm aware of that can't do a single one of those 4. Why?